Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia (Q87841217)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

title

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

main subject

acute myeloid leukemia

1 reference

Tibor J Kovacsovics

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

Alice Mims

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

Mohamed E Salama

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

Jeremy Pantin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

Narayanam Rao

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

Ken M Kosak

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

Peter Ahorukomeye

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

Martha J Glenn

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

Michael W N Deininger

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

Kenneth M Boucher

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

Linda M Bavisotto

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

Gerardo Gutierrez-Sanchez

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

Thomas P Kennedy

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

Stephen G Marcus

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

Paul J Shami

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

publication date

1 February 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

381-389

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

17 March 2020

cites work

1 reference

12 December 2020

Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia

1 reference

12 December 2020

Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine

1 reference

12 December 2020

The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34( ) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice

1 reference

12 December 2020

Characterization of the stromal cell-derived factor-1alpha-heparin complex

1 reference

12 December 2020

Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association

1 reference

12 December 2020

Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells.

1 reference

12 December 2020

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

12 December 2020

The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice

1 reference

12 December 2020

Protein-heparin interactions measured by BIAcore 2000 are affected by the method of heparin immobilization

1 reference

12 December 2020

The bicyclam AMD3100 story

1 reference

12 December 2020

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

12 December 2020

CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34 stem/progenitor cells to bone marrow

1 reference

12 December 2020

Platelet factor 4 enhances the adhesion of normal and leukemic hematopoietic stem/progenitor cells to endothelial cells

1 reference

12 December 2020

CXCR4 is a prognostic marker in acute myelogenous leukemia.

1 reference

12 December 2020

Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications

1 reference

12 December 2020

A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

1 reference

12 December 2020

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

1 reference

12 December 2020

Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands

1 reference

12 December 2020

Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting

1 reference

12 December 2020

Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies

1 reference

12 December 2020

Heparin-induced Leukocytosis Requires 6-O-Sulfation and Is Caused by Blockade of Selectin- and CXCL12 Protein-mediated Leukocyte Trafficking in Mice

1 reference

12 December 2020

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

1 reference

12 December 2020

Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH)

1 reference

12 December 2020

Platelet factor 4 platelet levels are inversely correlated with steady-state platelet counts and with platelet transfusion needs in pediatric leukemia patients

1 reference

12 December 2020

Molecular mechanisms underlying adhesion and migration of hematopoietic stem cells

1 reference

12 December 2020

The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers.

1 reference

12 December 2020

Heparin disrupts the CXCR4/SDF-1 axis and impairs the functional capacity of bone marrow-derived mononuclear cells used for cardiovascular repair

1 reference

12 December 2020

Heparin oligosaccharides inhibit chemokine (CXC motif) ligand 12 (CXCL12) cardioprotection by binding orthogonal to the dimerization interface, promoting oligomerization, and competing with the chemokine (CXC motif) receptor 4 (CXCR4) N terminus

1 reference

12 December 2020

Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML

1 reference

12 December 2020

CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia

1 reference

12 December 2020

Bone marrow stromal cells in the pathogenesis of acute myeloid leukemia

1 reference

12 December 2020

Cancer statistics, 2014

1 reference

12 December 2020

Acute myeloid leukemia: 2014 update on risk-stratification and management

1 reference

12 December 2020

Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells.

1 reference

12 December 2020

Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion.

1 reference

12 December 2020

10.1182/BLOODADVANCES.2017013391

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29467192 AND SRC:MED&resulttype=core&format=json

17 March 2020

PubMed publication ID

29467192

1 reference